Michel Sadelain Wins Tang Prize in Biopharmaceutical Science for Harnessing T Cells Against Cancer [Exclusive Interview]
NQ Score
49/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Michel Sadelain, a pioneer in cancer immunotherapy, has been awarded the Tang Prize in Biopharmaceutical Science for his groundbreaking development of CAR-T cell therapy. This innovative treatment reprograms patients' immune cells to target and destroy cancer, offering new hope for those with previously untreatable blood cancers and solid tumors.
AI Analysis
Frequently Asked Questions
- Q: What award did Michel Sadelain receive?
- A: He received the Tang Prize in Biopharmaceutical Science, awarded by Taiwan's Tang Prize Foundation.
- Q: When did CAR-T therapy start being used?
- A: It began with FDA-approved clinical trials in 2007, leading to clinical adoption.
- Q: Which patients benefit most from this therapy?
- A: It is most effective for blood cancer patients who failed conventional treatments.